VAC
MARRIOTT VACATIONS WORLDWIDE CORPORATION
stock NYSE

**RKLB (Rocket Lab)** — down hard, trading around $66-67, roughly 55% below its May 2026 high of $150.
• Shares fell about 11.7% after Piper Sandler initiated coverage with a Neutral rating, adding to existing investor anxiety, even as other analysts like Roth MKM stayed bullish, raising their price target to $130.
• Market concern centers on the pending $8 billion acquisition of Iridium Communications — specifically dilution risk and the $3.6 billion in bridge financing needed — plus a wave of insider selling, including by CEO Peter Beck.
• More broadly, it's part of a risk-off rotation hitting space stocks generally, despite strong operational results across the sector.
• Fundamentals actually look solid — Q1 revenue was $200M, up 63% YoY, with a $2.2B backlog. Next catalyst: estimated August 6 earnings report, with revenue projected around $232 million.
**UUUU (Energy Fuels)** — trading around $11.40, near the bottom of its 52-week range ($8.16–$27.90).
• Big story is the pivot from pure uranium into rare earths/critical minerals: Energy Fuels is entering the critical minerals space as the U.S. seeks to secure domestic sources of these materials, highlighted by its $1.9 billion deal to buy German magnet maker Vacuumschmelze (VAC).
• It also got conditional U.S. government support for rare earths growth in June, but analysts have been trimming price targets — Goldman Sachs cut theirs to $21 from $29 in June, while the CEO bought $968K of stock in late June.
• Q1 2026 earnings missed estimates (EPS -$0.04 vs -$0.02 expected); next earnings due August 5.
**SLS (SELLAS Life Sciences)** — this one's the wild card, up sharply, currently around $12-13, way up from single digits in June.
• Stock jumped after Alliance Global raised its price target to $25 from $10, reaffirming a Buy rating, spotlighting the Phase 3 REGAL trial in second-remission acute myeloid leukemia.
• Shares have run from the mid-$8s in late June to nearly $15 before settling near $13 — it trades like a classic high-beta, catalyst-driven biotech.
• CEO Angelos Stergiou has been actively pushing back on trial criticism ("let's separate the noise from the data") and made media appearances (Fox & Friends) ahead of AML trial data, fueling retail speculation about a potential Big Pharma buyout.
• Bottom line: this is a pure binary-catalyst trade — the whole move is speculation ahead of AML (
SLS009) readout data, so expect continued high volatility in either direction.
Quick gut-check: RKLB's selloff is more sentiment/dilution-driven than fundamentals, UUUU is a strategic pivot story people are still digesting, and SLS is a straight-up biotech data gamble — very different risk profiles despite all three moving hard this week.

**RKLB (Rocket Lab)** — down hard, trading around $66-67, roughly 55% below its May 2026 high of $150.
• Shares fell about 11.7% after Piper Sandler initiated coverage with a Neutral rating, adding to existing investor anxiety, even as other analysts like Roth MKM stayed bullish, raising their price target to $130.
• Market concern centers on the pending $8 billion acquisition of Iridium Communications — specifically dilution risk and the $3.6 billion in bridge financing needed — plus a wave of insider selling, including by CEO Peter Beck.
• More broadly, it's part of a risk-off rotation hitting space stocks generally, despite strong operational results across the sector.
• Fundamentals actually look solid — Q1 revenue was $200M, up 63% YoY, with a $2.2B backlog. Next catalyst: estimated August 6 earnings report, with revenue projected around $232 million.
**UUUU (Energy Fuels)** — trading around $11.40, near the bottom of its 52-week range ($8.16–$27.90).
• Big story is the pivot from pure uranium into rare earths/critical minerals: Energy Fuels is entering the critical minerals space as the U.S. seeks to secure domestic sources of these materials, highlighted by its $1.9 billion deal to buy German magnet maker Vacuumschmelze (VAC).
• It also got conditional U.S. government support for rare earths growth in June, but analysts have been trimming price targets — Goldman Sachs cut theirs to $21 from $29 in June, while the CEO bought $968K of stock in late June.
• Q1 2026 earnings missed estimates (EPS -$0.04 vs -$0.02 expected); next earnings due August 5.
**SLS (SELLAS Life Sciences)** — this one's the wild card, up sharply, currently around $12-13, way up from single digits in June.
• Stock jumped after Alliance Global raised its price target to $25 from $10, reaffirming a Buy rating, spotlighting the Phase 3 REGAL trial in second-remission acute myeloid leukemia.
• Shares have run from the mid-$8s in late June to nearly $15 before settling near $13 — it trades like a classic high-beta, catalyst-driven biotech.
• CEO Angelos Stergiou has been actively pushing back on trial criticism ("let's separate the noise from the data") and made media appearances (Fox & Friends) ahead of AML trial data, fueling retail speculation about a potential Big Pharma buyout.
• Bottom line: this is a pure binary-catalyst trade — the whole move is speculation ahead of AML (
SLS009) readout data, so expect continued high volatility in either direction.
Quick gut-check: RKLB's selloff is more sentiment/dilution-driven than fundamentals, UUUU is a strategic pivot story people are still digesting, and SLS is a straight-up biotech data gamble — very different risk profiles despite all three moving hard this week.